January 13, 2022

Minnesota Partnership awards 5 collaborative research grants for 2022

By Colette Gallagher

The Minnesota Partnership for Biotechnology and Medical Genomics have announced their 2022 research awardees. This marks the partnership's 18th year of spearheading new scientific ideas from Minnesota to improve the health of, and health care for, Minnesotans. The state-funded grants for these team science proposals total nearly $5 million. This year the awards fund innovative projects on heart and liver disease, mapping diseases of the brain, congenital genetic disease, and pancreatic cancer.

These two-year projects focus on improving treatment of diseases that affect Minnesotans. Projects are selected based on the quality and rigor of the proposed research, importance of the medical need and potential of future commercialization. The teams are comprised of researchers from Mayo Clinic and the University of Minnesota. It’s required that the studies be collaborative, and that the projects could not be pursued solely by either institution.

Eva Morava-Kozicz, M.D., Ph.D. a physician scientist in Mayo Clinic's Department of Clinical Genomics is one of the awardees. Dr. Morava-Kozicz conducts translational research in congenital disorders of glycosylation and mitochondrial disorders, and is developing dietary therapies in genetic disorders. She is an international expert who leads the Frontiers in Congenital Disorders of Glycosylation Consortium. Read more about her research.

Unexplored pathways: The impact of abnormal glycosylation on the hypothalamic-pituitary-adrenal and -gonadal axes and bone health in patients with congenital disorders of glycosylation.

Eva Morava-Kozicz, M.D., Ph.D. Mayo Clinic; Kyriakie Sarafoglou, M.D., University of Minnesota.

Disorders of glycosylation are genetic conditions that result in a range of developmental problems from early childhood and others as one reaches adult years. The mutations prevent proper function of the sugar-based building blocks in cells and can cause poor growth, poor muscle development, seizures, liver and heart disease and abnormal bleeding. This group wants to focus on understanding how this condition impacts the endocrine system, specifically four noted hormones that control types of growth and development.

The Minnesota Partnership for Biotechnology and Medical Genomics is a collaboration among the University of Minnesota, Mayo Clinic and the state of Minnesota.

Read more about the awardees.

Learn more

Read more stories about advances in individualized medicine.

Register to get weekly updates from the Mayo Clinic Center for Individualized Medicine blog.

Join the conversation

For more information, visit Mayo Clinic Center for Individualized Medicine, or Twitter at @MayoClinicCIM.



Tags: center for individualized medicine, genomics, mayo clinic, medical research, personalized medicine, Rare diseases

Contact Us · Privacy Policy